ArticleJACC. Advances2023
Effects of Vitamin K2 and D Supplementation on Coronary Artery Disease in Men: A RCT.
Article in JACC. Advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Vitamin K and vascular calcification: from biological plausibility to clinical realism.Clinical kidney journal · 2026Review
- The epigenetic potential of vitamin K2 in brain health.Epigenomics · 2025Review
- Current Knowledge of the Impact of Vitamin D in Coronary Artery Disease.International journal of molecular sciences · 2025Review
- Correlations Between Coronary Artery Calcium Scores and Vitamin A, the Triglyceride/High-Density Lipoprotein Ratio, and Glycated Hemoglobin in At-Risk Individuals in Saudi Arabia: A Comprehensive Cross-Sectional Study.Journal of clinical medicine · 2025Article
- Inactive Matrix Gla Protein and Cardiovascular Outcomes: The Multi-Ethnic Study of Atherosclerosis.Journal of the American Heart Association · 2025Article
- Matrix Gla protein and the long-term incidence and progression of coronary artery and aortic calcification in the Multi-Ethnic Study of Atherosclerosis.Atherosclerosis · 2024Article
- Vitamins to Treat Heart Disease: Can Coronary Calcium Progression Show Us the Path Forward?JACC. Advances · 2023Article
- Vitamin D and Vitamin K: Synergistic Roles and Emerging Evidence for Combined Supplementation.Journal of mid-life healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extent and progression of coronary artery calcification (CAC) are strong predictors of myocardial infarction and mortality. Objectives: This study aims to investigate if vitamin K2 and D supplementation can reduce CAC progression. Methods: A total of 389 participants were randomized to supplementation with vitamin K2 (720 μg/day) and D (25 μg/day) vs placebo in a multicenter double-blinded randomized controlled trial. The primary endpoint (progression of aortic valve calcification) has been reported. This study reports CAC progression in participants with no ischemic heart disease. CT scans were performed at baseline, 12, and 24 months. ΔCAC and coronary plaque volume were evaluated in the entire group and in 2 subgroups. A safety endpoint was the composite of myocardial infarction, coronary revascularization, and all-cause mortality. Results: In total, 304 participants (male, mean age 71 years) were identified. The intervention and placebo group both increased in mean CAC scores from baseline to 24-month follow-up (Δ203 vs Δ254 AU, Conclusions: Patients with no prior ischemic heart disease randomized to vitamin K2 and D supplementation had no significant reduction in mean CAC progression over a 2-year follow-up compared to placebo. Although the primary endpoint is neutral, differential responses to supplementation in those with CAC scores ≥400 AU and in safety endpoints are hypothesis-generating for future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.